Search

Your search keyword '"Iannelli, Chiara"' showing total 10 results
Start Over Author "Iannelli, Chiara"
10 results on '"Iannelli, Chiara"'

1. Diagnostic delay in adult coeliac disease: An Italian multicentre study

Author

Lenti, Marco Vincenzo, Aronico, Nicola, Bianchi, Paola Ilaria, D'Agate, Carmela Cinzia, Neri, Matteo, Volta, Umberto, Mumolo, Maria Gloria, Astegiano, Marco, Calabrò, Antonino Salvatore, Zingone, Fabiana, Latella, Giovanni, Di Sario, Antonio, Carroccio, Antonio, Ciacci, Carolina, Luzza, Francesco, Bagnato, Carmela, Fantini, Massimo Claudio, Elli, Luca, Cammarota, Giovanni, Gasbarrini, Antonio, Portincasa, Piero, Latorre, Mario Andrea, Petrucci, Clarissa, Quatraccioni, Claudia, Iannelli, Chiara, Vecchione, Nicoletta, Rossi, Carlo Maria, Broglio, Giacomo, Ianiro, Gianluca, Marsilio, Ilaria, Bibbò, Stefano, Marinoni, Beatrice, Tomaselli, Donatella, Abenavoli, Ludovico, Pilia, Riccardo, Santacroce, Giovanni, Lynch, Erica, Carrieri, Antonella, Mansueto, Pasquale, Gabba, Margherita, Alunno, Giacomo, Rossi, Chiara, Onnis, Francesca, Efthymakis, Konstantinos, Cesaro, Nicola, Vernero, Marta, Baiano Svizzero, Federica, Semeraro, Francesco Paolo, Silano, Marco, Vanoli, Alessandro, Klersy, Catherine, Corazza, Gino Roberto, and Di Sabatino, Antonio

Published
2023
Full Text
View/download PDF

2. Real-world efficacy and safety of vedolizumab in managing ulcerative colitis versus Crohn's disease: results from an Italian multicenter study

Author

Mocci, Giammarco, Tursi, Antonio, Maconi, Giovanni, Cataletti, Giovanni, Mantia, Beatrice, Serio, Mariaelena, Scarcelli, Antonella, Pagnini, Cristiano, Graziani, Maria Giovanna, Di Paolo, Maria Carla, Pranzo, Giuseppe, Luppino, Ileana, Paese, Pietro, Elisei, Walter, Monterubbianesi, Rita, Faggiani, Roberto, Ferronato, Antonio, Perini, Barbara, Savarino, Edoardo, Onidi, Francesca Maria, Binaghi, Laura, Usai Satta, Paolo, Schiavoni, Elisa, Napolitano, Daniele, Scaldaferri, Franco, Pugliese, Daniela, Pica, Roberta, Cocco, Andrea, Zippi, Maddalena, Rodino, Stefano, Sebkova, Ladislava, Rocco, Giulia, Sacchi, Carlotta, Zampaletta, Costantino, Gaiani, Federica, De Angelis, Gianluigi, Kayali, Stefano, Fanigliulo, Libera, Lorenzetti, Roberto, Allegretta, Leonardo, Scorza, Stefano, Cuomo, Antonio, Donnarumma, Laura, Della Valle, Nicola, Sacco, Rodolfo, Forti, Giacomo, Antonelli, Elisabetta, Bassotti, Gabrio, Iannelli, Chiara, Luzza, Francesco, Aragona, Giovanni, Perazzo, Patrizia, Lauria, Angelo, Piergallini, Simona, Colucci, Raffaele, Bianco, Maria Antonia, Meucci, Costantino, Giorgetti, Gianmarco, Clemente, Valeria, Fiorella, Serafina, Penna, Antonio, De Medici, Antonio, Picchio, Marcello, Papa, Alfredo, Scaldaferri, Franco (ORCID:0000-0001-8334-7541), Papa, Alfredo (ORCID:0000-0002-4186-7298), Mocci, Giammarco, Tursi, Antonio, Maconi, Giovanni, Cataletti, Giovanni, Mantia, Beatrice, Serio, Mariaelena, Scarcelli, Antonella, Pagnini, Cristiano, Graziani, Maria Giovanna, Di Paolo, Maria Carla, Pranzo, Giuseppe, Luppino, Ileana, Paese, Pietro, Elisei, Walter, Monterubbianesi, Rita, Faggiani, Roberto, Ferronato, Antonio, Perini, Barbara, Savarino, Edoardo, Onidi, Francesca Maria, Binaghi, Laura, Usai Satta, Paolo, Schiavoni, Elisa, Napolitano, Daniele, Scaldaferri, Franco, Pugliese, Daniela, Pica, Roberta, Cocco, Andrea, Zippi, Maddalena, Rodino, Stefano, Sebkova, Ladislava, Rocco, Giulia, Sacchi, Carlotta, Zampaletta, Costantino, Gaiani, Federica, De Angelis, Gianluigi, Kayali, Stefano, Fanigliulo, Libera, Lorenzetti, Roberto, Allegretta, Leonardo, Scorza, Stefano, Cuomo, Antonio, Donnarumma, Laura, Della Valle, Nicola, Sacco, Rodolfo, Forti, Giacomo, Antonelli, Elisabetta, Bassotti, Gabrio, Iannelli, Chiara, Luzza, Francesco, Aragona, Giovanni, Perazzo, Patrizia, Lauria, Angelo, Piergallini, Simona, Colucci, Raffaele, Bianco, Maria Antonia, Meucci, Costantino, Giorgetti, Gianmarco, Clemente, Valeria, Fiorella, Serafina, Penna, Antonio, De Medici, Antonio, Picchio, Marcello, Papa, Alfredo, Scaldaferri, Franco (ORCID:0000-0001-8334-7541), and Papa, Alfredo (ORCID:0000-0002-4186-7298)

Abstract

BackgroundVedolizumab (VDZ) can be used to treat refractory ulcerative colitis (UC) and Crohn's disease (CD). We assessed whether there are differences in treating UC vs CD with VDZ.Research design and methods Mayo score in UC and the Harvey-Bradshaw Index (HBI) in CD scored the clinical activity. Achievement and maintenance of clinical remission during the follow-up, and safety were the primary endpoints.Results729 patients (475 with UC and 254 with CD), median follow-up of 18 (IQR 6-36) months, were enrolled. Clinical remission at the 6(th) month of treatment was achieved in 488 (66.9%) patients (74.4% in CD vs 62.9% in UC, p<0.002) while, during the follow-up, no difference was found (81.5% in the UC group and 81.5% pts in the CD group; p=0.537). The clinical remission at the 6(th) month of treatment (p=0.001) and being naive to biologics (p<0.0001) were significantly associated with prolonged clinical remission. The clinical response was significantly higher in UC (90.1%) vs CD (84.3%) (p=0.023), and surgery occurred more frequently in CD (1.9% in UC vs 5.1% in CD, p=0.016).ConclusionWe found differences when using VDZ in UC vs CD in real life. These parameters can help the physician predict this drug's longterm efficacy.

Published
2023

3. Real-world efficacy and safety of vedolizumab in managing ulcerative colitis versus Crohn’s disease: results from an Italian multicenter study

Author

Mocci, Giammarco, primary, Tursi, Antonio, additional, Maconi, Giovanni, additional, Cataletti, Giovanni, additional, Mantia, Beatrice, additional, Serio, Mariaelena, additional, Scarcelli, Antonella, additional, Pagnini, Cristiano, additional, Graziani, Maria Giovanna, additional, Di Paolo, Maria Carla, additional, Pranzo, Giuseppe, additional, Luppino, Ileana, additional, Paese, Pietro, additional, Elisei, Walter, additional, Monterubbianesi, Rita, additional, Faggiani, Roberto, additional, Ferronato, Antonio, additional, Perini, Barbara, additional, Savarino, Edoardo, additional, Onidi, Francesca Maria, additional, Binaghi, Laura, additional, Usai Satta, Paolo, additional, Schiavoni, Elisa, additional, Napolitano, Daniele, additional, Scaldaferri, Franco, additional, Pugliese, Daniela, additional, Pica, Roberta, additional, Cocco, Andrea, additional, Zippi, Maddalena, additional, Rodino, Stefano, additional, Sebkova, Ladislava, additional, Rocco, Giulia, additional, Sacchi, Carlotta, additional, Zampaletta, Costantino, additional, Gaiani, Federica, additional, De Angelis, Gianluigi, additional, Kayali, Stefano, additional, Fanigliulo, Libera, additional, Lorenzetti, Roberto, additional, Allegretta, Leonardo, additional, Scorza, Stefano, additional, Cuomo, Antonio, additional, Donnarumma, Laura, additional, Della Valle, Nicola, additional, Sacco, Rodolfo, additional, Forti, Giacomo, additional, Antonelli, Elisabetta, additional, Bassotti, Gabrio, additional, Iannelli, Chiara, additional, Luzza, Francesco, additional, Aragona, Giovanni, additional, Perazzo, Patrizia, additional, Lauria, Angelo, additional, Piergallini, Simona, additional, Colucci, Raffaele, additional, Bianco, Maria Antonia, additional, Meucci, Costantino, additional, Giorgetti, Gianmarco, additional, Clemente, Valeria, additional, Fiorella, Serafina, additional, Penna, Antonio, additional, De Medici, Antonio, additional, Picchio, Marcello, additional, and Papa, Alfredo, additional

Published
2023
Full Text
View/download PDF

4. From advanced diagnosis to advanced resection in early neoplastic colorectal lesions: Never-ending and trending topics in the 2020s

Author

Auriemma, Francesco, primary, Sferrazza, Sandro, additional, Bianchetti, Mario, additional, Savarese, Maria Flavia, additional, Lamonaca, Laura, additional, Paduano, Danilo, additional, Piazza, Nicole, additional, Giuffrida, Enrica, additional, Mete, Lupe Sanchez, additional, Tucci, Alessandra, additional, Milluzzo, Sebastian Manuel, additional, Iannelli, Chiara, additional, Repici, Alessandro, additional, and Mangiavillano, Benedetto, additional

Published
2022
Full Text
View/download PDF

6. Comparison of performances of infliximab biosimilars CT-P13 versus SB2 in the treatment of inflammatory bowel diseases: a real-life multicenter, observational study in Italy

Author

Tursi, Antonio, primary, Mocci, Giammarco, additional, Allegretta, Leonardo, additional, Aragona, Giovanni, additional, Bianco, Maria Antonia, additional, Colucci, Raffaele, additional, Cuomo, Antonio, additional, Della Valle, Nicola, additional, Ferronato, Antonio, additional, Forti, Giacomo, additional, Gaiani, Federica, additional, Graziani, Maria Giovanna, additional, Lorenzetti, Roberto, additional, Luzza, Francesco, additional, Paese, Pietro, additional, Penna, Antonio, additional, Pica, Roberta, additional, Pranzo, Giuseppe, additional, Rodinò, Stefano, additional, Scarcelli, Antonella, additional, Zampaletta, Costantino, additional, Brozzi, Lorenzo, additional, Cicerone, Clelia, additional, Cocco, Andrea, additional, De’ Angelis, Gianluigi, additional, Donnarumma, Laura, additional, Fiorella, Serafina, additional, Iannelli, Chiara, additional, Larussa, Tiziana, additional, Le Grazie, Marco, additional, Luppino, Ileana, additional, Meucci, Costantino, additional, FaggianI, Roberto, additional, Pagnini, Cristiano, additional, Perazzo, Patrizia, additional, Rodriguez-Castro, Kryssia Isabel, additional, Sacco, Rodolfo, additional, Sebkova, Ladislava, additional, Serio, Mariaelena, additional, De Monti, Alberta, additional, Picchio, Marcello, additional, Napolitano, Daniele, additional, Schiavoni, Elisa, additional, Turchini, Laura, additional, Scaldaferri, Franco, additional, Pugliese, Daniela, additional, Guidi, Luisa, additional, Laterza, Lucrezia, additional, Privitera, Giuseppe, additional, Pizzoferrato, Marco, additional, Lopetuso, Loris R., additional, Armuzzi, Alessandro, additional, Elisei, Walter, additional, Maconi, Giovanni, additional, and Papa, Alfredo, additional

Published
2021
Full Text
View/download PDF

7. Real-life burden of adverse reactions to biological therapy in inflammatory bowel disease: a single-centre prospective case series

Author

Larussa, Tiziana, primary, Basile, Antonio, primary, Palleria, Caterina, primary, Iannelli, Chiara, primary, Vero, Ada, primary, Giubilei, Lidia, primary, De Sarro, Caterina, primary, Suraci, Evelina, primary, Marasco, Raffaella, primary, Imeneo, Maria, primary, Russo, Emilio, primary, Abenavoli, Ludovico, primary, De Sarro, Giovambattista, primary, and Luzza, Francesco, primary

Published
2021
Full Text
View/download PDF

10. Comparison of performances of infliximab biosimilars CT-P13 versus SB2 in the treatment of inflammatory bowel diseases: a real-life multicenter, observational study in Italy

Author

Tursi, Antonio, Mocci, Giammarco, Allegretta, Leonardo, Aragona, Giovanni, Bianco, Maria Antonia, Colucci, Raffaele, Cuomo, Antonio, Della Valle, Nicola, Ferronato, Antonio, Forti, Giacomo, Gaiani, Federica, Graziani, Maria Giovanna, Lorenzetti, Roberto, Luzza, Francesco, Paese, Pietro, Penna, Antonio, Pica, Roberta, Pranzo, Giuseppe, Rodinò, Stefano, Scarcelli, Antonella, Zampaletta, Costantino, Brozzi, Lorenzo, Cicerone, Clelia, Cocco, Andrea, De’ Angelis, Gianluigi, Donnarumma, Laura, Fiorella, Serafina, Iannelli, Chiara, Larussa, Tiziana, Le Grazie, Marco, Luppino, Ileana, Meucci, Costantino, FaggianI, Roberto, Pagnini, Cristiano, Perazzo, Patrizia, Rodriguez-Castro, Kryssia Isabel, Sacco, Rodolfo, Sebkova, Ladislava, Serio, Mariaelena, De Monti, Alberta, Picchio, Marcello, Napolitano, Daniele, Schiavoni, Elisa, Turchini, Laura, Scaldaferri, Franco, Pugliese, Daniela, Guidi, Luisa, Laterza, Lucrezia, Privitera, Giuseppe, Pizzoferrato, Marco, Lopetuso, Loris R., Armuzzi, Alessandro, Elisei, Walter, Maconi, Giovanni, and Papa, Alfredo

Abstract

ABSTRACTBackgroundTo compare the performances of Infliximab (IFX) biosimilar CT-P13 and SB2 in the treatment of Inflammatory Bowel Diseases (IBD) outpatients in Italy.Research Design and MethodsThree hundred and eighty IBD outpatients were retrospectively evaluated. The primary endpoint was to compare the two IFX biosimilars in terms of reaching and maintenance of remission at any timepoint.Results197 patients with Ulcerative Colitis (UC) and 183 patients with Crohn’s Disease (CD) treated with CT-P13 or SB2 and having a median (IQR) follow-up of 12 (6–36) months were compared: 230 (60.5%) were naïve to anti-TNFα, 20 (5.26%) were switched from IFX originator or from IFX CT-P13 to IFX SB2. Clinical remission was achieved in 133 (67.5%) UC patients and in 164 (89.6%) CD patients (p < 0.000), with no differences between CT-P13 and SB2 in the rate of remission in UC (p = 0.667) and CD (p = 0.286). Clinical response, steroid-free remission, rate of surgery, mucosal healing (MH) in UC, switching from IFX originator or from other biosimilar, and safety were similar. Higher MH rate was obtained in CD patients treated with CT-P13 (p = 0.004).ConclusionThis first comparative study found that both IFX biosimilars CT-P13 and SB2 are effective and safe in managing IBD outpatients.

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results